SYNGENEUpdated 5 Sept 2026, 0:39

Syngene International Ltd

SYNGENEUpdated 5 Sept 2026, 0:39

Market Cap

₹15,979Cr.

Current Price

₹396

High / Low

₹679/375

Stock P/E

53.2

ROE7.71%

ROCE9.91%

Book Value₹117

Face Value₹10.0

Dividend Yield0.32%

About

Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.[1]

Quarterly results

Last reported quarters₹ Cr.

Profit & loss

Annual statement₹ Cr.

Shareholding pattern

As of Jun 2026%

Shareholding trend

Ownership over time%

Balance sheet

Assets & liabilities₹ Cr.

Cash flows

Operating, investing & financing₹ Cr.

Key ratios

Historical financial ratios

Category	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	76	61	60	68	68	72	57	71	55	49	51	46
Inventory Days	59	44	37	82	30	18	41	87	141	95	62	60
Days Payable	106	87	116	194	154	157	166	115	110	104	143	136
Cash Conversion Cycle	29	18	-19	-44	-56	-67	-68	44	86	41	-30	-30
Working Capital Days	-64	-65	-44	-48	-103	-172	-65	-43	21	-30	-59	-76
ROCE %	23%	20%	18%	16%	17%	17%	14%	13%	15%	13%	13%	10%

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 5 September 2026 at 0:39

SYNGENE INTERNATIONAL LTD (SYNGENE) financials — quarterly results, P&L, cash flow, balance sheet, shareholding